The CONCLUDE trial
The CONCLUDE trial addresses an important knowledge gap, providing head-to-head data for two long-acting insulin analogs – insulin degludec and insulin glargine 300. The insulins will be tested in people with type 2 diabetes that is poorly controlled on basal insulin with or without oral diabetes medications.
Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).
Results from the CONCLUDE trial were presented at the 55th EASD Annual Meeting (EASD 2019):
CONCLUDE: A trial COmparing the efficacy aNd safety of insulin degLUDEc and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin and oral antidiabetic drugs
Thursday, September 19, 12:00–13:00. Joslin Hall, Fira Barcelona Gran Via, Spain
Session Chair: T. Heise, Germany
- Rationale, trial design and methods. T. R. Pieber, Austria
- Results. A. Philis-Tsimikas, USA
- Commentary. S. Del Prato, Italy